Robert Crane

Microchips Biotech, Inc. develops drug delivery systems and bio sensing devices. Its technologies are designed to transform electromechanical medical devices into highly tuned biochemical sensing and therapy systems. The company was founded by Terrance G. McGuire, Michael J. Cima, John T. Santini, Jr. and Robert S. Langer, Jr. in 1999 and is headquartered in Lexington, MA.

Protein Forest, Inc., a privately held company founded in 2002 and is located in Lexington, MA, is a developer and manufacturer of state-of-the-art sample fractionation technology, products, and data analysis software for mass spectrometry. The company develops, manufactures, and markets instruments, consumables, and bioinformatics software products for scientists in the life science, drug discovery, pharmaceutical, biotech, and diagnostic industries around the world.

GI Dynamics, Inc. engages in the development and commercialization of a medical device system intended for treatment of patients with type 2 diabetes and reduction of obesity. Its pipeline product is EndoBarrier, an endoscopically delivered medical device intended to help restore healthy blood sugar levels and reduce weight. The company was founded by Andy Levine on March 24, 2003 and is headquartered in Boston, MA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Part of Ligand Pharmaceuticals, Inc., Seragen, Inc. develops drugs. The private company is based in Westerly, RI. Seragen was acquired by Ligand Pharmaceuticals, Inc. on August 12, 1998 for $57.96 million.

CB Biomedical, Inc. develops and produces novel bioartificial organs based on proprietary mammalian cell and semi permeable membrane technologies. The company is headquartered in Lexington, MA